TGF-β inactivation and TGF-α overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer

International Journal of Cancer

Volumn 127, Issue 5, 2010, Pages 1060-1071

  Baek, Ji Yeon ^a,b   Morris, Shelli M ^b   Campbell, Jean ^c   Fausto, Nelson ^c   Yeh, Matthew M ^c   Grady, William M ^b,c  

^a National Cancer Center   (South Korea)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hepatocellular carcinoma; Raf kinase inhibitor protein; Raf signaling; Transforming growth factor ; Transforming growth factor

Indexed keywords

B RAF KINASE INHIBITOR; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; CRE RECOMBINASE; INTEGRASE; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE FREQUENCY; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRASES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

EID: 77955475948     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25127     Document Type: Article

References (56)

1. Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2005;10:269-81.
2. Farazi PA, Depinho RA. The genetic and environmental basis of hepatocellular carcinoma. Discov Med 2006;6:182-6.
3. Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006;240:157-69.
4. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25:3787-800.
5. Grady WM, Markowitz S. TGF-β signaling pathway in tumor suppression. In: Derynck R, Miyazano K, eds. The TGF-β family. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2008. 889-938.
6. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-8.
7. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-α/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-β receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3:1059-66.
8. Park YN, Chae KJ, Oh BK, Choi J, Choi KS, Park C. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-β. Hepatogastroenterology 2004;51:396-400.
9. Hirohashi S, Ishak K, Kojiro M, Wanless I, Theise N, Tsukuma H, Blum H, Deugnier Y, Laurent Puig P, Fischer H, Sakamoto M. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, eds. Pathology and genetics of tumours of the digestive system, vol. 1. Lyon: IARC Press, 2000. 159-72.
10. Bierie B, Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev 2006;17:29-40.
11. Munoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, Moses HL, Grady WM. Transforming growth factor β receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006;66:9837-44.
12. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-28.
13. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGF α overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990;61:1137-46.
14. Santoni-Rugiu E, Jensen MR, Factor VM, Thorgeirsson SS. Acceleration of c-myc-induced hepatocarcinogenesis by coexpression of transforming growth factor (TGF)-α in transgenic mice is associated with TGF-β1 signaling disruption. Am J Pathol 1999;154:1693-700.
15. Yeh MM, Larson AM, Campbell JS, Fausto N, Rulyak SJ, Swanson PE. The expression of transforming growth factor-α in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Am J Surg Pathol 2007;31:681-9.
16. Bos J. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
17. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
18. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006;131:1208-17.
19. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
20. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFβ/Smad signaling in oncogenic Ras. Genes Dev 1999;13:804-16.
21. Javelaud D, Delmas V, Moller M, Sextius P, Andre J, Menashi S, Larue L, Mauviel A. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 2005;24:7624-9.
22. Calonge MJ, Massague J. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-β antiproliferative responses in colon cancer cells. J Biol Chem 1999;274:33637-43.
23. Calvisi DF, Thorgeirsson SS. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005;33:181-4.
24. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006;16:451-6.
25. Chytil A, Magnuson M, Wrigth C, Moses H. Conditional Inactivation of the TGF-b Type II Receptor Using Cre:Lox. Genesis 2002;32:73-5.
26. Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 2000;26:149-50.
27. Romero-Gallo J, Sozmen EG, Chytil A, Russell WE, Whitehead R, Parks TW, Holdren MS, Her MF, Gautam S, Magnuson M, Moses HL, Grady WM. Inactivation of TGF-β signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene 2005;24:3028-41.
28. Takagi H, Sharp R, Hammermeister C, Goodrow T, Bradley MO, Fausto N, Merlino G. Molecular and genetic analysis of liver oncogenesis in transforming growth factor α transgenic mice. Cancer Res 1992;52:5171-7.
29. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, Gautam S, Moses HL, Grady WM. Transforming growth factor β receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004;64:4687-92.
30. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M, Kosma VM. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004;40:1485-95.
31. Grady WM, Willis JE, Trobridge P, Romero-Gallo J, Munoz N, Olechnowicz J, Ferguson K, Gautam S, Markowitz SD. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer 2006;118:600-8.
32. Chytil A, Magnuson MA, Wright CV, Moses HL. Conditional inactivation of the TGF-β type II receptor using Cre:Lox. Genesis 2002;32:73-5.
33. Dumenco L, Oguey D, Wu J, Messier N, Fausto N. Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology 1995;22:1279-88.
34. Alexandrow M, Moses H. Transforming growth factor β and cell cycle regulation. Cancer Res 1995;55:1452-7.
35. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993;196:1010-16.
36. Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N, Namba M. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res 2001;21:657-62.
37. Talarmin H, Rescan C, Cariou S, Glaise D, Zanninelli G, Bilodeau M, Loyer P, Guguen-Guillouzo C, Baffet G. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. Mol Cell Biol 1999;19:6003-11.
38. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004;91:169-200.
39. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-κB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol Cell Biol 2001;21:7207-17.
40. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006;25:1125-42.
41. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47:2059-67.
42. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72 (Suppl 1):30-44.
43. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar A-R, Muller WJ, Moses HL. Effect of conditional knockout of the type II TGFB receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005;65:2296-302.
44. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
45. Mishra B, Tang Y, Katuri V, Fleury T, Said AH, Rashid A, Jogunoori W, Mishra L. Loss of cooperative function of transforming growth factor-β signaling proteins, smad3 with embryonic liver fodrin, a β-spectrin, in primary biliary cirrhosis. Liver Int 2004;24:637-45.
46. Keller ET, Fu Z, Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 2004;68:1049-53.
47. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 2005;94:273-8.
48. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res 2008;18:452-7.
49. Hu Z, Evarts RP, Fujio K, Omori N, Omori M, Marsden ER, Thorgeirsson SS. Expression of transforming growth factor α/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis 1996;17:931-8.
50. Harada K, Shiota G, Kawasaki H. Transforming growth factor-α and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19:318-25.
51. Okano J, Matsumoto K, Nagahara T, Murawaki Y. Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. J Gastroenterol 2006;41:166-76.
52. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000;20:3079-85.
53. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol 2007;179:5441-53.
54. Kurisaki K, Kurisaki A, Valcourt U, Terentiev AA, Pardali K, Ten Dijke P, Heldin CH, Ericsson J, Moustakas A. Nuclear factor YY1 inhibits transforming growth factor β- and bone morphogenetic protein-induced cell differentiation. Mol Cell Biol 2003;23:4494-510.
55. Siegel P, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003;3:807-21.
56. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007;22 Supp; 1:S20-27.